{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:36:14Z","timestamp":1781177774410,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In neovascular age-related macular degeneration (nAMD) the exact amount of fluid and its location on optical coherence tomography (OCT) have been defined as crucial biomarkers for disease activity and therapeutic decisions. Yet in the absence of quantitative evaluation tools, real-world care outcomes are disappointing. Artificial intelligence (AI) offers a practical option for clinicians to enhance point-of-care management by analysing OCT volumes in a short time. In this protocol we present the prospective implementation of an AI-algorithm providing automated real-time fluid quantifications in a clinical real-world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective, multicentre, randomized (1:1) and double masked phase III clinical trial. Two-hundred-ninety patients with active nAMD will be randomized between a study arm using AI-supported fluid quantifications and another arm using conventional qualitative assessments, i.e. state-of-the-art disease management. The primary outcome is defined as the mean number of injections over 1 year. Change in BCVA is defined as a secondary outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Automated measurement of fluid volumes in all retinal compartments such as intraretinal fluid (IRF), and subretinal fluid (SRF) will serve as an objective tool for clinical investigators on which to base retreatment decisions. Compared to qualitative fluid assessment, retreatment decisions will be plausible and less prone to error or large variability. The underlying hypothesis is that fluid should be treated, while residual persistent or stable amounts of fluid may not benefit from further therapy. Reducing injection numbers without diminishing the visual benefit will increase overall patient safety and relieve the burden for healthcare providers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial-registration<\/jats:title><jats:p>EudraCT-Number: 2019-003133-42<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41433-022-02154-8","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T19:03:21Z","timestamp":1657047801000},"page":"1464-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)\u2014a phase III, prospective, multicentre, randomized study: design and methods"],"prefix":"10.1038","volume":"37","author":[{"given":"Leonard M.","family":"Coulibaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sacu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-0894","authenticated-orcid":false,"given":"Hrvoje","family":"Bogunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Faustmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-4015","authenticated-orcid":false,"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-7311","authenticated-orcid":false,"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2154_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"2154_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris 3rd","year":"2013","unstructured":"Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844\u201351.","journal-title":"Ophthalmology"},{"key":"2154_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","volume":"3","author":"KL Pennington","year":"2016","unstructured":"Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016;3:34.","journal-title":"Eye Vis (Lond)"},{"key":"2154_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OPTH.S1959","volume":"2","author":"MS Spitzer","year":"2008","unstructured":"Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P. Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol. 2008;2:1\u201314.","journal-title":"Clin Ophthalmol"},{"key":"2154_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2154_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27:787\u201394.","journal-title":"Eye (Lond)"},{"key":"2154_CR7","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2217\/cer-2018-0058","volume":"7","author":"DH Jaffe","year":"2018","unstructured":"Jaffe DH, Chan W, Bezlyak V, Skelly A. The economic and humanistic burden of patients in receipt of current available therapies for nAMD. J Comp Eff Res. 2018;7:1125\u201332.","journal-title":"J Comp Eff Res"},{"key":"2154_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ajo.2011.05.008","volume":"152","author":"S Day","year":"2011","unstructured":"Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 2011;152:1014\u201320.","journal-title":"Am J Ophthalmol"},{"key":"2154_CR9","first-page":"156","volume":"137","author":"GJ Jaffe","year":"2004","unstructured":"Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma, American Journal of Ophthalmology. Elsevier Inc. 2004;137:156\u201369.","journal-title":"Elsevier Inc"},{"key":"2154_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamaophthalmol.2015.4948","volume":"134","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, et al. Correlation of 3-dimensionally quantified intraretinal and subretinal fluid with visual acuity in neovascular age-related macular degeneration. JAMA Ophthalmol. 2016;134:182\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"2154_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retin. 2018;2:645\u201353.","journal-title":"Ophthalmol Retin"},{"key":"2154_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retinal Eye Res. 2016;50:1\u201324.","journal-title":"Prog Retinal Eye Res"},{"key":"2154_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ophtha.2015.09.013","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U. Predictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMD. Ophthalmology. 2016;123:60\u20139.","journal-title":"Ophthalmology"},{"key":"2154_CR14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","volume":"41","author":"GS Reiter","year":"2021","unstructured":"Reiter GS, Grechenig C, Vogl WD, Guymer RH, Arnold JJ, Bogunovic H, et al. Analysis of fluid volume and its impact on visual acuity in the FLUID study as quantified with deep learning. Retina. 2021;41:1318\u201328.","journal-title":"Retina"},{"key":"2154_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 2019;126:723\u201334.","journal-title":"Ophthalmology"},{"key":"2154_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","volume":"35","author":"CA Toth","year":"2015","unstructured":"Toth CA, DeCroos FC, Ying GS, Stinnett SS, Heydary CS, Burns R, et al. Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials (CATT). Retina 2015;35:1303.","journal-title":"Retina"},{"key":"2154_CR17","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3892\/etm.2020.9313","volume":"20","author":"AD Moraru","year":"2020","unstructured":"Moraru AD, Costin D, Moraru RL, Branisteanu DC. Artificial intelligence and deep learning in ophthalmology - present and future (Review). Exp Ther Med. 2020;20:3469\u201373.","journal-title":"Exp Ther Med"},{"key":"2154_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.07.004","volume":"67","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovi\u0107 H. Artificial intelligence in retina. Prog Retinal Eye Res Elsevier Ltd. 2018;67:1\u201329.","journal-title":"Prog Retinal Eye Res Elsevier Ltd"},{"key":"2154_CR19","unstructured":"Age-Related Macular Degeneration PPP 2019 - American Academy of Ophthalmology [Internet]. [cited 2021 Dec 13]. Available from: https:\/\/www.aao.org\/preferred-practice-pattern\/age-related-macular-degeneration-ppp."},{"key":"2154_CR20","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"2154_CR21","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983\u201390.","journal-title":"Eye"},{"key":"2154_CR22","unstructured":"Mathew W MacCumber M. Real-World Injection Intervals in Wet AMD. Special Report - Retina Today [Internet]. 2020 May [cited 2022 Jun 7]; Available from: https:\/\/retinatoday.com\/articles\/2020-may-june\/real-world-injection-intervals-in-wet-amd."},{"key":"2154_CR23","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, van Everen SA, Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181\u201392.","journal-title":"Ophthalmology"},{"key":"2154_CR24","first-page":"398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open. Ophthalmology. 2019;4:398.","journal-title":"Ophthalmology"},{"key":"2154_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","volume":"192","author":"M Okada","year":"2018","unstructured":"Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH. The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol. 2018;192:184\u201397.","journal-title":"Am J Ophthalmol"},{"key":"2154_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"2154_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2017.05.014","volume":"180","author":"W Ou","year":"2017","unstructured":"Ou W, Brown D, Payne J, Wykoff C. Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol. 2017;180:8\u201317.","journal-title":"Am J Ophthalmol"},{"key":"2154_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/bjophthalmol-2020-317416","volume":"106","author":"M Michl","year":"2020","unstructured":"Michl M, Fabianska M, Seeb\u00f6ck P, Sadeghipour A, Najeeb BH, Bogunovic H, et al. Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy. Br J Ophthalmol. 2020;106:113\u201320.","journal-title":"Br J Ophthalmol"},{"key":"2154_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated quantitative assessment of retinal fluid volumes as important biomarkers in neovascular age-related macular degeneration. Am J Ophthalmol. 2021;224:267\u201381.","journal-title":"Am J Ophthalmol"},{"key":"2154_CR30","first-page":"5187","volume":"61","author":"H Bogunovic","year":"2020","unstructured":"Bogunovic H, Seaman J, Margaron P, Seeb\u00f6ck P, Gerendas BSS, Lorand D, et al. Detection of retinal fluids in OCT scans by an automated deep learning algorithm compared to human expert grading in the HAWK & HARRIER trials. Investigative Ophthalmol Vis Sci. 2020;61:5187\u20135187.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"2154_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","volume":"128","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agr\u00f3n E, et al. Retinal specialist versus artificial intelligence detection of retinal fluid from OCT: age-related eye disease study 2: 10-year follow-on study. Ophthalmology. 2021;128:100\u20139.","journal-title":"Ophthalmology"},{"key":"2154_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip AM, et al. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology. 2018;125:549\u201358.","journal-title":"Ophthalmology"},{"key":"2154_CR33","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1111\/aos.12832","volume":"94","author":"KT Tsaousis","year":"2016","unstructured":"Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmologica 2016;94:e353\u20135.","journal-title":"Acta Ophthalmologica"},{"key":"2154_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/APO.0000000000000363","volume":"10","author":"SS Sim","year":"2021","unstructured":"Sim SS, Yip MYT, Wang Z, Tan ACS, Tan GSW, Cheung CMG, et al. Digital technology for amd management in the post-covid-19 new normal. Asia-Pac J Ophthalmol 2021;10:39\u201348.","journal-title":"Asia-Pac J Ophthalmol"},{"key":"2154_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajo.2020.06.028","volume":"19","author":"O Trivizki","year":"2020","unstructured":"Trivizki O, Karp MR, Chawla A, Yamanuha J, Gregori G, Rosenfeld PJ. Eliminating visual acuity and dilated fundus examinations improves cost efficiency of performing optical coherence tomogrpahy\u2013guided intravitreal injections. Am J Ophthalmol. 2020;19:222.","journal-title":"Am J Ophthalmol"},{"key":"2154_CR36","doi-asserted-by":"crossref","unstructured":"de Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nature Medicine 2018 24:9 [Internet]. 2018 Aug 13 [cited 2021 Dec 13];24(9):1342\u201350. Available from: https:\/\/www.nature.com\/articles\/s41591-018-0107-6.","DOI":"10.1038\/s41591-018-0107-6"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02154-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02154-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T06:14:51Z","timestamp":1700806491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02154-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2154"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02154-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"US-E is a scientific consultant for Genentech, Heidelberg Engineering, Kodiak, Novartis, RetInSight and Roche. GSR received research funds outside this work from RetInSight. HB reported receiving financial research support outside this work from Apellis Pharmaceuticals, Inc, and Heidelberg Engineering GmbH, as well as speaker fees from Bayer, Roche, and Apellis. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was obtained from the ethical commission of the Medical University Vienna on 30.08.2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}